The U.S. Food and Drug Administration (FDA) has approved Armodafinil Tablets
developed by Lupin Pharmaceuticals.
Armodafinil Tablets are the generic version of Cephalon’s
Nuvigil Tablets, which Lupin has been approved to market in the U.S.
The doses for Armodafinil Tablets that have been approved by
the FDA are 50 mg, 150 mg, 200 mg and 250 mg. LPI plans to begin the promotion
of its newly approved drug in the U.S. in the very near future. The medication
is designed to improve wakefulness in adult patients who suffer from excessive
sleepiness that is linked to obstructive sleep apnea, narcolepsy or swift
work disorder.
As of September, U.S. sales for Nuvigil Tablets,
Armodafinil Tablet’s name brand counterpart, are $515.6
million.
FDA approves Armodafinil Tablets in U.S.
Alerts Sign-up